A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia

MLA

Daniel J. DeAngelo, et al. “A Phase II Study of the EGFR Inhibitor Gefitinib in Patients with Acute Myeloid Leukemia.” Leukemia Research, vol. 38, no. 4, Mar. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7d7911f0466e34ba02ed7b7094f335b5&authtype=sso&custid=ns315887.

APA

Daniel J. DeAngelo, Ilene Galinsky, Martha Wadleigh, Jacob E. Berchuck, Kimberly Stegmaier, Philip C. Amrein, L. Andres Sirulnik, Richard Stone, Todd R. Golub, & Donna Neuberg. (2013). A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leukemia Research, 38(4).

Chicago

Daniel J. DeAngelo, Ilene Galinsky, Martha Wadleigh, Jacob E. Berchuck, Kimberly Stegmaier, Philip C. Amrein, L. Andres Sirulnik, Richard Stone, Todd R. Golub, and Donna Neuberg. 2013. “A Phase II Study of the EGFR Inhibitor Gefitinib in Patients with Acute Myeloid Leukemia.” Leukemia Research 38 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7d7911f0466e34ba02ed7b7094f335b5&authtype=sso&custid=ns315887.